LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 13

Search options

  1. Article ; Online: The Promise of Multicancer Early Detection. Comment on Pons-Belda et al. Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm. Diagnostics 2021, 11 , 2171

    Eric A. Klein / Tomasz M. Beer / Michael Seiden

    Diagnostics, Vol 12, Iss 1243, p

    2022  Volume 1243

    Abstract: Multicancer Early Detection (MCED) represents a new and exciting paradigm for the early detection of cancer, which is the leading cause of death worldwide. Current screening tests, recommended for only five cancer types (breast, lung, colon, cervical, ... ...

    Abstract Multicancer Early Detection (MCED) represents a new and exciting paradigm for the early detection of cancer, which is the leading cause of death worldwide. Current screening tests, recommended for only five cancer types (breast, lung, colon, cervical, and prostate), are limited by a lack of complete adherence to guideline-based use and by the fact that they have cumulative high false positive rates. MCED tests agnostically detect cancer signals in the blood with good sensitivity and low false positive rates, can predict the cancer site of origin with high accuracy, can detect highly lethal cancers that have no current screening tests, and promise to improve cancer screening by improving efficiency and reducing the overall number needed to screen. Herein we outline this promise and clarify several published misconceptions about this field.
    Keywords multicancer early detection ; methylation ; circulating cell-free genome atlas ; Medicine (General) ; R5-920
    Subject code 610
    Language English
    Publishing date 2022-05-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  2. Article ; Online: Study protocol for the Exercising Together© trial

    Kerri M. Winters-Stone / Karen S. Lyons / Nathan F. Dieckmann / Christopher S. Lee / Zahi Mitri / Tomasz M. Beer

    Trials, Vol 22, Iss 1, Pp 1-

    a randomized, controlled trial of partnered exercise for couples coping with cancer

    2021  Volume 16

    Abstract: Abstract Background Most cancer survivors are married, and cancer strains the physical and mental health of each partner and their intimate relationship. We created a partnered strength training program, Exercising Together©, where the survivor and his/ ... ...

    Abstract Abstract Background Most cancer survivors are married, and cancer strains the physical and mental health of each partner and their intimate relationship. We created a partnered strength training program, Exercising Together©, where the survivor and his/her partner exercise as a team in order to improve physical and mental health of both members of the couple as well as the quality of their relationship. We have not yet determined if Exercising Together© is similarly effective in couples coping with different types of cancer nor if training as a team has unique and added benefits over those derived from supervised group training and/or shared behavior change. The purpose of this study is to determine the unique benefits of Exercising Together© on physical, mental, and relational health in couples coping with breast, prostate, or colorectal cancer. Methods Survivors of prostate, breast and colorectal cancer (N = 294, 98 per cancer site) and their intimate, co-residing partners are recruited to participate in a single-blind, parallel group, randomized trial comparing three exercise groups that train twice per week for 6 months. Couples are randomized to one of three groups: (1) Exercising Together© where partners train as a team in a supervised group setting; (2) separate supervised group exercise classes for survivors or partners, respectively; (3) unsupervised home exercise program provided to each partner. The primary outcome is relationship quality (dyadic coping by the Dyadic Coping scale, emotional intimacy by the Dyadic Adjustment Scale, physical intimacy by the Physical Intimacy Behavior Scale, and symptom incongruence). Secondary outcomes are physical health (% body fat by DXA, serum fasting lipids (triglycerides, HDL, and LDL cholesterol), insulin resistance (HOMA-IR), resting blood pressure, C-reactive protein, TNF alpha, and physical functioning by the short Physical Performance Battery and SF-36) and mental health (depressive symptoms, anxiety, fear of recurrence) of each partner. Outcomes are collected at baseline, mid (3 months), post-intervention (6 months), and follow-up (12 months). Discussion Exercising Together© could shift the paradigm of survivorship care toward novel couple-based approaches that could optimize outcomes for each partner because their health is interdependent on each other and their relationship. Trial registration ClinicalTrials.gov NCT03630354 . Registered August 14, 2018
    Keywords Cancer survivor ; Dyad ; Caregiver ; Exercise ; Physical activity ; Physical functioning ; Medicine (General) ; R5-920
    Subject code 796
    Language English
    Publishing date 2021-08-01T00:00:00Z
    Publisher BMC
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: Protocol for GET FIT Prostate

    Kerri M. Winters-Stone / Fuzhong Li / Fay Horak / Nathan Dieckmann / Arthur Hung / Christopher Amling / Tomasz M. Beer

    Trials, Vol 22, Iss 1, Pp 1-

    a randomized, controlled trial of group exercise training for fall prevention and functional improvements during and after treatment for prostate cancer

    2021  Volume 13

    Abstract: Abstract Background Many prostate cancer survivors are treated with androgen deprivation therapy (ADT), but these therapies may increase frailty, worsen physical functioning, and increase fall risk. While exercise may counter functional declines ... ...

    Abstract Abstract Background Many prostate cancer survivors are treated with androgen deprivation therapy (ADT), but these therapies may increase frailty, worsen physical functioning, and increase fall risk. While exercise may counter functional declines associated with ADT, no studies have tested whether and which type of exercise may reduce falls and frailty. The purpose of this trial is to compare the relative efficacy of strength training versus tai ji quan training against each other and to a stretching control group on falls, frailty, and physical functioning in men expose to ADT for prostate cancer. Methods Prostate cancer survivors treated with ADT (N = 360) who have fallen in the past year or are at risk of a fall based on validated risk factors will be recruited to participate in this single-blind, parallel group, randomized trial. Participants will be randomized to one of three supervised, group training programs: (i) strength training, (ii) tai ji quan training, or (iii) stretching (control), that train 3×/week for 6 months. Outcomes are assessed at baseline, 3 (mid-intervention), 6 (immediately post-intervention), and 12 (follow-up) months. The primary outcome is falls assessed by monthly self-report. Secondary outcomes include the following: frailty (low lean body mass (by bioelectrical impedance analysis), exhaustion (by SF-36 vitality scale), low activity (by CHAMPS physical activity survey), slowness (by 4 m usual walk speed), and weakness (by chair stand time)); objective and subjective measures of physical function will also be collected. Negative binomial regression models will be used to assess differences in falls between groups, while mixed effects modeling will be used to compare the relative efficacy of training group on secondary outcomes. Discussion Exercise represents a non-pharmacologic approach to mitigate the problem of falls experienced among men treated with ADT. By engaging in appropriate exercise, men may be able to avoid or delay falls, frailty, and disability associated with their ...
    Keywords Prostate cancer ; Falls ; Frailty ; Exercise ; Physical activity ; Medicine (General) ; R5-920
    Subject code 796
    Language English
    Publishing date 2021-11-01T00:00:00Z
    Publisher BMC
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article ; Online: A pilot feasibility study of Exercising Together© during radiation therapy for prostate cancer

    Kerri M. Winters-Stone / Karen S. Lyons / Tomasz M. Beer / Meghan B. Skiba / Arthur Hung

    Pilot and Feasibility Studies, Vol 7, Iss 1, Pp 1-

    a dyadic approach for patients and spouses

    2021  Volume 15

    Abstract: Abstract Introduction Prostate cancer can negatively impact the health of patients and their spouse, particularly early on in the cancer trajectory. Purpose To determine the feasibility and acceptability of dyadic exercises during radiation therapy and ... ...

    Abstract Abstract Introduction Prostate cancer can negatively impact the health of patients and their spouse, particularly early on in the cancer trajectory. Purpose To determine the feasibility and acceptability of dyadic exercises during radiation therapy and preliminary efficacy on physical, mental, and relational outcomes for men and their spouses. Exercising Together©, originally designed as a 6-month dyadic resistance training program for couples post-treatment, was adapted for the radiation setting. Methods We conducted a single-group pilot feasibility study of Exercising Together© in men scheduled for radiation therapy for prostate cancer and their spouse. Couples attended supervised exercise sessions thrice weekly throughout radiation treatment and were followed up 8 weeks later. Primary outcomes were feasibility and acceptability with secondary outcomes of changes in physical (physical functioning (short physical performance battery (sPPB)), gait speed (m/s), functional capacity (400-m walk (min), physical activity (min/week)), mental (depressive symptoms (CES-D), and anxiety (SCL-90 ANX)), and relationship (Dyadic Coping, Role Overload, and Physical Intimacy Behavior Scales) health outcomes for each partner. Participants completed an evaluation post-intervention. Results Ten couples enrolled and 8 completed the intervention, attending 83% of scheduled sessions. Couple satisfaction with the intervention was high (patients: mean difference (MD) = 9.4 ± 1.9 and spouses: MD = 10.0 ± 0.0, on a 1–10 scale). At post-intervention, gait speed (MD = 0.1; 95%CI: 0.1, 0.2; p = 0.003; d = 0.94) and functional capacity (MD = −0.6; 95%CI: −0.9, 0.3; p = 0.002; d = −0.42) improved in patients and sPPB in spouses (MD = 1.3; 95%CI: 0.3, 2.2; p = 0.02; d = 0.71). Total physical activity increased non-significantly for patients and significantly for spouses at post-intervention and decreased at follow-up (MD = 179.6; 95%CI: 55.4, 303.7; p = 0.01; d = 1.35 and MD = −139.9; 95%CI: −266.5, 13.3; p = 0.03; d=1.06). Among patients, ...
    Keywords Prostate cancer ; Exercise ; Physical function ; Mental health ; Relationship ; Dyad ; Medicine (General) ; R5-920
    Subject code 796
    Language English
    Publishing date 2021-12-01T00:00:00Z
    Publisher BMC
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article ; Online: HIF1 and ID1 Interplay Confers Adaptive Survival to HIF1α-Inhibition

    Hao Geng / Hyun-Kyung Ko / Janet Pittsenbarger / Christopher T. Harvey / Changhui Xue / Qiong Liu / Sadie Wiens / Sushant K. Kachhap / Tomasz M. Beer / David Z. Qian

    Frontiers in Cell and Developmental Biology, Vol

    2021  Volume 9

    Abstract: Hypoxia is a universal pathological feature of solid tumors. Hypoxic tumor cells acquire metastatic and lethal phenotypes primarily through the activities of hypoxia-inducible factor 1 alpha (HIF1α). Therefore, HIF1α is considered as a promising ... ...

    Abstract Hypoxia is a universal pathological feature of solid tumors. Hypoxic tumor cells acquire metastatic and lethal phenotypes primarily through the activities of hypoxia-inducible factor 1 alpha (HIF1α). Therefore, HIF1α is considered as a promising therapeutic target. However, HIF inhibitors have not proven to be effective in clinical testing. The underlying mechanism is unclear. We report that oncogenic protein ID1 is upregulated in hypoxia by HIF1α shRNA or pharmacological inhibitors. In turn, ID1 supports tumor growth in hypoxia in vitro and in xenografts in vivo, conferring adaptive survival response and resistance. Mechanistically, ID1 proteins interfere HIF1-mediated gene transcription activation, thus ID1 protein degradation is accelerated by HIF1α-dependent mechanisms in hypoxia. Inhibitions of HIF1α rescues ID1, which compensates the loss of HIF1α by the upregulation of GLS2 and glutamine metabolism, thereby switching the metabolic dependency of HIF1α -inhibited cells from glucose to glutamine.
    Keywords ID1 ; hypoxia ; resistance ; HIF1 ; targeted-treatment ; Biology (General) ; QH301-705.5
    Language English
    Publishing date 2021-11-01T00:00:00Z
    Publisher Frontiers Media S.A.
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  6. Article ; Online: Publisher Correction

    Hao Geng / Changhui Xue / Janet Mendonca / Xiao-Xin Sun / Qiong Liu / Patrick N. Reardon / Yingxiao Chen / Kendrick Qian / Vivian Hua / Alice Chen / Freddy Pan / Julia Yuan / Sang Dang / Tomasz M. Beer / Mu-Shui Dai / Sushant K. Kachhap / David Z. Qian

    Nature Communications, Vol 10, Iss 1, Pp 1-

    Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy

    2019  Volume 1

    Abstract: The original version of this Article contained errors in Fig. 7. In panels e and f, the graph titles incorrectly read ‘LNCaP-AdtNs’ and ‘LAPC4-AdtNs’, respectively. These errors have now been corrected in both the PDF and HTML versions of the Article. ...

    Abstract The original version of this Article contained errors in Fig. 7. In panels e and f, the graph titles incorrectly read ‘LNCaP-AdtNs’ and ‘LAPC4-AdtNs’, respectively. These errors have now been corrected in both the PDF and HTML versions of the Article.
    Keywords Science ; Q
    Language English
    Publishing date 2019-01-01T00:00:00Z
    Publisher Nature Publishing Group
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article ; Online: Publisher Correction

    Hao Geng / Changhui Xue / Janet Mendonca / Xiao-Xin Sun / Qiong Liu / Patrick N. Reardon / Yingxiao Chen / Kendrick Qian / Vivian Hua / Alice Chen / Freddy Pan / Julia Yuan / Sang Dang / Tomasz M. Beer / Mu-Shui Dai / Sushant K. Kachhap / David Z. Qian

    Nature Communications, Vol 10, Iss 1, Pp 1-

    Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy

    2019  Volume 1

    Abstract: The original version of this Article contained errors in Fig. 7. In panels e and f, the graph titles incorrectly read ‘LNCaP-AdtNs’ and ‘LAPC4-AdtNs’, respectively. These errors have now been corrected in both the PDF and HTML versions of the Article. ...

    Abstract The original version of this Article contained errors in Fig. 7. In panels e and f, the graph titles incorrectly read ‘LNCaP-AdtNs’ and ‘LAPC4-AdtNs’, respectively. These errors have now been corrected in both the PDF and HTML versions of the Article.
    Keywords Science ; Q
    Language English
    Publishing date 2019-01-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Article ; Online: Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer

    Nancy Devlin / Michael Herdman / Marco Pavesi / De Phung / Shevani Naidoo / Tomasz M. Beer / Bertrand Tombal / Yohann Loriot / Cristina Ivanescu / Teresa Parli / Mark Balk / Stefan Holmstrom

    Health and Quality of Life Outcomes, Vol 15, Iss 1, Pp 1-

    an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial

    2017  Volume 9

    Abstract: Abstract Background The effect of enzalutamide on health-related quality of life (HRQoL) in the PREVAIL trial in chemotherapy-naïve men with metastatic castration-resistant prostate cancer was analyzed using the generic EQ-5D instrument. Methods Patients ...

    Abstract Abstract Background The effect of enzalutamide on health-related quality of life (HRQoL) in the PREVAIL trial in chemotherapy-naïve men with metastatic castration-resistant prostate cancer was analyzed using the generic EQ-5D instrument. Methods Patients received oral enzalutamide 160 mg/day (n = 872) or placebo (n = 845). EQ-5D index and EQ-5D visual analogue scale (EQ-5D VAS) scores were evaluated at baseline, week 13, and every 12 weeks until week 61 due to sample size reduction thereafter. Changes on individual dimensions were assessed, and Paretian Classification of Health Change (PCHC) and time-to-event analyses were conducted. Results With enzalutamide, EQ-5D index and EQ-5D VAS scores declined more slowly versus placebo and time to diverge from full health was prolonged. Average decline in EQ-5D index (−0.042 vs. –0.070; P < .0001) and EQ-5D VAS (−1.3 vs. –4.4; P < .0001) was significantly smaller with enzalutamide. There were significant (P < .05) between-group differences favoring enzalutamide in Pain/Discomfort to week 37, Anxiety/Depression at week 13, and Usual Activities at week 25, but no significant differences for Mobility and Self-care. The PCHC analysis showed more enzalutamide patients reporting improvement than placebo patients at weeks 13, 25, and 49 (all P < .05) and week 37 (P = .0512). Enzalutamide was superior (P ≤ .0003) to placebo for time to diverge from full health and time to first deterioration on Pain/Discomfort and Anxiety/Depression dimensions. Conclusions This in-depth post hoc analysis showed that enzalutamide delayed HRQoL deterioration and had beneficial effects on several HRQoL domains, including Pain/Discomfort and the proportion of patients in full health, compared with placebo, and may help to support future analyses of this type. Trial registration NCT01212991
    Keywords Metastatic castration-resistant prostate cancer ; Enzalutamide ; Quality of life ; Eq-5D ; Computer applications to medicine. Medical informatics ; R858-859.7
    Subject code 610
    Language English
    Publishing date 2017-06-01T00:00:00Z
    Publisher BMC
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article: Effects of ω-3 Fatty Acids and Catechins on Fatty Acid Synthase in the Prostate: A Randomized Controlled Trial

    Zhang, Zhenzhen / Jackilen Shannon / Mark Garzotto / Motomi Mori / Paige E. Farris / Philippe Thuillier / Stephen Lieberman / Tomasz M. Beer / Wesley A. Stoller

    Nutrition and cancer. 2016 Nov. 16, v. 68, no. 8

    2016  

    Abstract: Animal and human studies suggest fish oil and green tea may have protective effect on prostate cancer. Fatty acid synthase (FAS) has been hypothesized to be linked to chemoprotective effects of both compounds. This study evaluated the independent and ... ...

    Abstract Animal and human studies suggest fish oil and green tea may have protective effect on prostate cancer. Fatty acid synthase (FAS) has been hypothesized to be linked to chemoprotective effects of both compounds. This study evaluated the independent and joint effects of fish oil (FO) and green tea supplement (epigallocatechin-3-gallate, EGCG) on FAS and Ki-67 levels in prostate tissue. Through a double-blinded, randomized controlled trial with 2 × 2 factorial design, 89 men scheduled for repeat prostate biopsy following an initial negative prostate biopsy were randomized into either FO alone (1.9 g DHA + EPA/day), EGCG alone (600 mg/day), a combination of FO and EGCG, or placebo. We used linear mixed-effects models to test the differences of prostate tissue FAS and Ki-67 by immunohistochemistry between pre- and post-intervention within each group, as well as between treatment groups. Results did not show significant difference among treatment groups in pre-to-post-intervention changes of FAS (P = 0.69) or Ki-67 (P = 0.26). Comparing placebo group with any of the treatment groups, we did not find significant difference in FAS or Ki-67 changes (all P > 0.05). Results indicate FO or EGCG supplementation for a short duration may not be sufficient to produce biologically meaningful changes in FAS or Ki-67 levels in prostate tissue.
    Keywords biopsy ; fatty-acid synthase ; fish oils ; flavanols ; green tea ; humans ; immunohistochemistry ; men ; models ; omega-3 fatty acids ; placebos ; prostatic neoplasms ; protective effect ; randomized clinical trials
    Language English
    Dates of publication 2016-1116
    Size p. 1309-1319.
    Publishing place Taylor & Francis
    Document type Article
    ZDB-ID 2025822-7
    ISSN 1532-7914 ; 0163-5581
    ISSN (online) 1532-7914
    ISSN 0163-5581
    DOI 10.1080/01635581.2016.1224365
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  10. Article ; Online: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy

    Hao Geng / Changhui Xue / Janet Mendonca / Xiao-Xin Sun / Qiong Liu / Patrick N. Reardon / Yingxiao Chen / Kendrick Qian / Vivian Hua / Alice Chen / Freddy Pan / Julia Yuan / Sang Dang / Tomasz M. Beer / Mu-Shui Dai / Sushant K. Kachhap / David Z. Qian

    Nature Communications, Vol 9, Iss 1, Pp 1-

    2018  Volume 16

    Abstract: Prostate cancer often develops resistance to androgen receptor (AR) targeting drugs. Here, the authors show that, under conditions of hypoxia, AR inhibition via enzalutamide increases the expression of the glycolytic enzyme phosphoglucose isomerase (GPI) ...

    Abstract Prostate cancer often develops resistance to androgen receptor (AR) targeting drugs. Here, the authors show that, under conditions of hypoxia, AR inhibition via enzalutamide increases the expression of the glycolytic enzyme phosphoglucose isomerase (GPI) promoting a metabolic rewiring that allows the cells to survive, and consistent GPI inhibition restores sensitivity to enzalutamide.
    Keywords Science ; Q
    Language English
    Publishing date 2018-11-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top